FDA commissioner
This article was originally published in The Rose Sheet
Executive Summary
Appointment not likely for "several months," HHS Secretary Tommy Thompson maintains during National Press Club appearance April 17. "We are looking for researchers, and we want to get some input from some of the research organizations, so that is going to take a little bit longer," he states, citing lengthy procedural issues in nomination process. Same-day New York Times editorial by former FDA Deputy Commissioner for Policy William Schultz links nomination delay to Bush Administration's interest in re-reviewing safety of abortifacient RU-486, encourages Administration to "bite the bullet" and "get on with the business of nominating" a commissioner